US HB5668 | 2019-2020 | 116th Congress
Status
Spectrum: Slight Partisan Bill (Republican 2-1)
Status: Engrossed on November 18 2020 - 50% progression, died in committee
Action: 2020-11-18 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Engrossed) [PDF]
Status: Engrossed on November 18 2020 - 50% progression, died in committee
Action: 2020-11-18 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Engrossed) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act to modernize the labeling of certain generic drugs, and for other purposes.
Title
MODERN Labeling Act of 2020 Making Objective Drug Evidence Revisions for New Labeling Act of 2020
Sponsors
Rep. Doris Matsui [D-CA] | Rep. Brett Guthrie [R-KY] | Rep. Nicholas Taylor [R-TX] |
History
Date | Chamber | Action |
---|---|---|
2020-11-18 | Senate | Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
2020-11-17 | House | Motion to reconsider laid on the table Agreed to without objection. |
2020-11-17 | House | On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806) |
2020-11-17 | House | DEBATE - The House proceeded with forty minutes of debate on H.R. 5668. |
2020-11-17 | House | Considered under suspension of the rules. (consideration: CR H5805-5807) |
2020-11-17 | House | Mr. Pallone moved to suspend the rules and pass the bill, as amended. |
2020-11-16 | House | Placed on the Union Calendar, Calendar No. 471. |
2020-11-16 | House | Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573. |
2020-07-15 | House | Ordered to be Reported (Amended) by Voice Vote. |
2020-07-15 | House | Committee Consideration and Mark-up Session Held. |
2020-03-11 | House | Subcommittee Consideration and Mark-up Session Held. |
2020-03-11 | House | Ordered to be Reported (Amended) by Voice Vote. |
2020-01-25 | House | Referred to the Subcommittee on Health. |
2020-01-24 | House | Referred to the House Committee on Energy and Commerce. |
2020-01-24 | House | Introduced in House |
Same As/Similar To
SB1895 (Related) 2019-07-08 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 133.
SB1897 (Related) 2019-06-19 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
SB4796 (Related) 2020-10-05 - Read twice and referred to the Committee on Finance.
HB8527 (Related) 2020-10-02 - Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
SB1897 (Related) 2019-06-19 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
SB4796 (Related) 2020-10-05 - Read twice and referred to the Committee on Finance.
HB8527 (Related) 2020-10-02 - Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Subjects
Congressional oversight
Drug safety, medical device, and laboratory regulation
Health
Prescription drugs
Drug safety, medical device, and laboratory regulation
Health
Prescription drugs